

HIGHER EFFICACY MEDICATION IN BIO-EXPOSED ULCERATIVE COLITIS PATIENTS: TRIDENT-UC STUDY

Tiago Filipe Almeida Franco Leal

UEG Week Berlin 2025

Poster

IBD

October 4, 2025

In a multicenter real-world study of 259 ulcerative colitis patients who failed at least one advanced therapy, upadacitinib demonstrated superior outcomes compared to ustekinumab and tofacitinib at multiple timepoints.

KEY POINTS

- At week 16, upadacitinib showed higher steroid-free clinical remission than both ustekinumab (OR 2.1, $p=0.014$) and tofacitinib (OR 2.1, $p=0.040$), though no difference was observed at week 52.
- Upadacitinib achieved higher biochemical remission at week 16 versus ustekinumab (OR 2.3, $p=0.015$) and tofacitinib (OR 2.1, $p=0.039$), with this advantage persisting at week 52 (OR 4.7 and 4.6 respectively).
- At week 52, upadacitinib was associated with higher endoscopic remission than ustekinumab (OR 3.6, $p=0.036$), while both ustekinumab and upadacitinib showed higher endoscopic remission than tofacitinib at week 16.
- In subanalysis of second-line therapy after anti-TNF failure, upadacitinib demonstrated higher steroid-free clinical remission than tofacitinib (OR 3.6, $p=0.035$) and higher endoscopic remission at week 52 than tofacitinib (OR 12.0, $p=0.017$).
- This retrospective study is relevant for gastroenterologists managing moderate-to-severe ulcerative colitis patients who have failed prior biologic therapy.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/cf4d372e-a815-11f0-8879-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.